Resistance mechanisms of tumour cells to EGFR inhibitors

被引：0
作者：
Floriana Morgillo
Flavia Cantile
Morena Fasano
Teresa Troiani
Erika Martinelli
Fortunato Ciardiello
机构：
[1] Seconda Università degli studi di Napoli,Dipartimento di Internistica clinica e sperimentale “F. Magrassi A. Lanzara”
来源：
Clinical and Translational Oncology | 2009年 / 11卷
关键词：
EGFR; Monoclonal antibody; Tyrosine kinase inhibitor; Resistance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
In spite of the overexpression and efficient inhibition of epidermal growth factor receptor (EGFR), resistance to EGFR inhibitors, monoclonal antibodies and tyrosine kinase inhibitors may occur. Understanding the molecular mechanisms affecting cancer cell sensitivity or resistance to EGFR inhibitors may be of help in deciding on treatment and in new translational studies. This review will focus on the most relevant mechanisms contributing to the acquisition of sensitivity/resistance to EGFR inhibitors.
引用
收藏
页码：270 / 275
页数：5
相关论文
共 172 条
[1]  
Bogdan S.(2001)Epidermal growth factor receptor signaling Curr Biol 11 292-295
[2]  
Klambt C.(2005)Biomarkers for prediction of sensitivity to EGFR inhibitors in nonsmall cell lung cancer Curr Opin Oncol 17 118-122
[3]  
Hirsch F.R.(2002)ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy Cancer Res 62 5749-5754
[4]  
Witta S.(2001)Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody Oncogene 20 1913-1922
[5]  
Wakeling A.E.(2002)The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides Cancer Res. 62 3151-3158
[6]  
Guy S.P.(2007)Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab J Clin Oncol. 25 3230-3237
[7]  
Woodburn J.R.(2008)Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGFbinding proteins J Clin Invest 118 2609-2619
[8]  
Liu B.(2004)Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme Clin Cancer Res 10 3216-3224
[9]  
Fang M.(2004)Mutant epidermal growth factor receptor displays increased signalling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin Oncogene 23 4594-4602
[10]  
Lu Y.(2004)Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib N Engl J Med 350 2129-2139
12345678910